| A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy (NCT01058512) | Cellectar Biosciences, Inc. | 2010-03-01 |
| A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 (NCT01074008) | AbbVie (prior sponsor, Abbott) | 2010-03-01 |
| Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1) (NCT01937728) | Kaohsiung Medical University Chung-Ho Memorial Hospital | 2010-03-01 |
| Notification of Donors With Positive Microbiology Markers (NCT01050881) | NHS Blood and Transplant | 2010-03-01 |
| A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004) (NCT00998985) | Merck Sharp & Dohme LLC | 2010-02-23 |
| UCLA-Amity Parolee Health Promotion Study (NCT01844414) | University of California, Los Angeles | 2010-02-01 |
| A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C (NCT00814606) | University of Chicago | 2010-02-01 |
| Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders (NCT01051921) | Conatus Pharmaceuticals Inc. | 2010-01-01 |
| A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults (NCT01038167) | Vertex Pharmaceuticals Incorporated | 2010-01-01 |
| Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients (NCT01054729) | Gilead Sciences | 2010-01-01 |
| Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2) (NCT01054742) | Merck Sharp & Dohme LLC | 2009-12-01 |
| Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment (NCT01052701) | Johns Hopkins University | 2009-12-01 |
| Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects (NCT00987337) | Pfizer | 2009-11-01 |
| Study of a Novel Therapeutic Vaccine for Hepatitis C Virus (NCT01094873) | ReiThera Srl | 2009-11-01 |
| A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4) (NCT00959699) | Merck Sharp & Dohme LLC | 2009-11-01 |
| A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment (NCT00980330) | Tibotec Pharmaceuticals, Ireland | 2009-10-01 |
| Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients (NCT00993122) | University of Roma La Sapienza | 2009-10-01 |
| Intravenous Interferon During Liver Transplant (NCT01192698) | Wake Forest University Health Sciences | 2009-10-01 |
| VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers (NCT00973388) | Tibotec BVBA | 2009-10-01 |
| Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV (NCT00983853) | Vertex Pharmaceuticals Incorporated | 2009-10-01 |
| A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and Methadone (NCT00915564) | Tibotec Pharmaceuticals, Ireland | 2009-09-01 |
| Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load (NCT00977054) | National Taiwan University Hospital | 2009-09-01 |
| SPC3649 Multiple Dose Study in Healthy Volunteers (NCT00979927) | Santaris Pharma A/S | 2009-09-01 |
| Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C (NCT00938860) | Novartis Pharmaceuticals | 2009-09-01 |
| Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 (NCT00996216) | GlaxoSmithKline | 2009-09-01 |
| VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram (NCT00933894) | Tibotec BVBA | 2009-09-01 |
| Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure (NCT01033045) | Fundacion IMIM | 2009-09-01 |
| Micro RNA-122 and the Clinical Course of Patients With Chronic Hepatitis C (NCT00980161) | National Taiwan University Hospital | 2009-09-01 |
| Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3) (NCT00984620) | Boehringer Ingelheim | 2009-09-01 |
| Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072 (NCT00982826) | Abbott | 2009-09-01 |
| Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C (NCT00951223) | Kadmon Corporation, LLC | 2009-08-01 |
| Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects (NCT00958152) | Vertex Pharmaceuticals Incorporated | 2009-08-01 |
| Clinical Performance of Abbott RealTime Hepatitis C Virus (HCV) Genotype II Test (NCT00979979) | National Taiwan University Hospital | 2009-07-01 |
| Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive (NCT00945880) | Eiger BioPharmaceuticals | 2009-07-01 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients (NCT00947349) | Boehringer Ingelheim | 2009-07-01 |
| A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005) (NCT01010906) | Merck Sharp & Dohme LLC | 2009-07-01 |
| Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation (NCT00947440) | Abbott | 2009-07-01 |
| Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV (NCT00926146) | University of California, Los Angeles | 2009-07-01 |
| VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir. (NCT00903773) | Tibotec BVBA | 2009-06-01 |
| A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment (NCT00882908) | Tibotec Pharmaceuticals, Ireland | 2009-06-01 |
| Injecting Drug Use Community Intervention Trial (NCT01108614) | National Center for AIDS/STD Control and Prevention, China CDC | 2009-06-01 |
| Virology Follow up Study in Subjects Previously Treated With Telaprevir (NCT00916474) | Vertex Pharmaceuticals Incorporated | 2009-06-01 |
| CTS-1027 in Interferon-Naive Hepatitis C Patients (NCT00925990) | Conatus Pharmaceuticals Inc. | 2009-06-01 |
| Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection (NCT00547716) | University of Missouri, Kansas City | 2009-06-01 |
| Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C (NCT00919633) | Medtronic Corporate Technologies and New Ventures | 2009-06-01 |
| A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection (NCT01091077) | Massachusetts General Hospital | 2009-06-01 |
| Drug-Drug Interaction Study in Healthy Subjects (NCT00904059) | Bristol-Myers Squibb | 2009-05-01 |
| Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV) (NCT00892697) | Weill Medical College of Cornell University | 2009-05-01 |
| An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes (NCT00722423) | US Department of Veterans Affairs | 2009-05-01 |
| A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016) (NCT00880763) | Merck Sharp & Dohme LLC | 2009-04-20 |
| Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection (NCT00911963) | Vertex Pharmaceuticals Incorporated | 2009-04-01 |
| Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection (NCT00879047) | University of California, San Francisco | 2009-04-01 |
| Study of Maternal Hepatitis C Infection and Influenza Vaccination in Pregnancy (NCT00810875) | University of California, San Francisco | 2009-04-01 |
| Nutritional Support During Antiviral Therapy for Hepatitis C (NCT00841243) | UMC Utrecht | 2009-03-01 |
| A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV) (NCT00812331) | Tibotec Pharmaceuticals, Ireland | 2009-03-01 |
| TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins. (NCT00866853) | Tibotec Pharmaceuticals, Ireland | 2009-03-01 |
| VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer (NCT00828789) | Tibotec BVBA | 2009-02-01 |
| Long-term Follow-up of HALT-C Sustained Virological Responders (NCT00825877) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2009-01-15 |
| Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices (NCT00657397) | French National Agency for Research on AIDS and Viral Hepatitis | 2009-01-01 |
| Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy (NCT01024894) | Cytheris SA | 2009-01-01 |
| A Pilot Study of High-Dose, Intravenous Ascorbic Acid (Vitamin C) to Treat Hepatitis C (NCT01250743) | Health Innovations, Frontier Research Institute | 2009-01-01 |
| Sonazoid Enhanced Liver Cancer Trial for Early Detection (NCT00822991) | Kindai University | 2009-01-01 |
| An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN) (NCT00704756) | Merck Sharp & Dohme LLC | 2009-01-01 |
| Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed) (NCT00725842) | Merck Sharp & Dohme LLC | 2009-01-01 |
| Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy (NCT00781274) | Tanabe Pharma Corporation | 2008-12-01 |
| The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC (NCT00926120) | Brooke Army Medical Center | 2008-12-01 |
| Cell Bound Complement Activation Proteins as Markers of Liver Injury (NCT01025531) | University of Pittsburgh | 2008-12-01 |
| Lifestyle Intervention Targetting Obesity and Insulin Resistance in Chronic Hepatitis C (NCT00755742) | University Health Network, Toronto | 2008-11-01 |
| An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria (NCT02515279) | Hoffmann-La Roche | 2008-11-01 |
| Effects of Motivational Interviewing on Risky Injecting Practices Among Injecting Drug Users (IDUs) (NCT00794391) | Université de Sherbrooke | 2008-11-01 |
| Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C (NCT00780416) | Tanabe Pharma Corporation | 2008-11-01 |
| A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response (NCT00758043) | Vertex Pharmaceuticals Incorporated | 2008-10-01 |
| Study the Relationship Between Obesity and Hepatitis C Replication (NCT01157975) | University of California, San Diego | 2008-10-01 |
| A Study of MDX-1106 to Treat Patients With Hepatitis C Infection (NCT00703469) | Bristol-Myers Squibb | 2008-10-01 |
| A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults (NCT00752687) | Abbott | 2008-09-01 |
| Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba (NCT00926614) | Brooke Army Medical Center | 2008-09-01 |
| Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients (NCT00871845) | Hossam Kandil | 2008-09-01 |
| A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection (NCT00720434) | Pfizer | 2008-08-01 |
| Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C (NCT01272479) | Istanbul University | 2008-08-01 |
| Identifying the Gaps in the Diagnosis and Management of Hepatitis C (NCT00976781) | Henry Ford Health System | 2008-08-01 |
| Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007) (NCT00704184) | Merck Sharp & Dohme LLC | 2008-07-25 |
| Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002) (NCT00730431) | Merck Sharp & Dohme LLC | 2008-07-01 |
| Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone (NCT01025297) | Cytheris SA | 2008-07-01 |
| TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule (NCT00752648) | Tibotec Pharmaceuticals, Ireland | 2008-07-01 |
| Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1) (NCT00724451) | Merck Sharp & Dohme LLC | 2008-07-01 |
| Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy (NCT00747539) | University of California, Los Angeles | 2008-07-01 |
| Genetic Analysis of Liver Cancer (NCT00768001) | Samuel So | 2008-06-01 |
| Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis (NCT01909778) | Boehringer Ingelheim | 2008-06-01 |
| VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state. (NCT00775125) | Tibotec BVBA | 2008-06-01 |
| FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation (NCT00701272) | University Health Network, Toronto | 2008-06-01 |
| TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing. (NCT00741169) | Tibotec Pharmaceuticals, Ireland | 2008-06-01 |
| Safety Study of SPC3649 in Healthy Men (NCT00688012) | Santaris Pharma A/S | 2008-05-01 |
| Hepatitis C Virus (HCV) Treatment Completion or Withdrawal (NCT00674492) | US Department of Veterans Affairs | 2008-05-01 |
| A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C (NCT00630058) | Tanabe Pharma Corporation | 2008-04-01 |
| Investigation of Hepatitis B and Hepatitis C in Taiwan (NCT00946010) | National Taiwan University Hospital | 2008-04-01 |
| Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy (NCT01045278) | Region Skane | 2008-04-01 |
| Efficacy of an Exercise Intervention to Decrease Depressive Symptoms in Veterans With Hepatitis C (NCT00643695) | Portland VA Medical Center | 2008-03-01 |
| Treatment of Acute Hepatitis C Virus in HIV Co-Infection (NCT00845676) | University of California, San Francisco | 2008-03-01 |
| Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients (NCT00655226) | Icahn School of Medicine at Mount Sinai | 2008-03-01 |
| A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) (NCT00627926) | Vertex Pharmaceuticals Incorporated | 2008-03-01 |